(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 January 2014 (16.01.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/011750 A1

(51) International Patent Classification:
A61K 31/47 (2006.01)

(21) International Application Number:
PCT/US2013/049894

(22) International Filing Date:
10 July 2013 (10.07.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/670,268 11 July 2012 (11.07.2012) US

(71) Applicant *(for BB only)*: **TEVA PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petach Tikva (IL).

(71) Applicant *(for all designated States except BB, US)*: **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US).

(72) Inventors; and
(71) Applicants *(for US only)*: **SARFATII, Gadi** [IL/IL]; Kibbutz Beit Guvrin (IL). **LOVINGER, Ioana** [IL/IL]; Rh. Tel Hai 98/3, 44245 Kfar Saba (IL). **LICHT, Danit** [IL/IL]; Rh. Keren Haysod 1, Givat Shmuel (IL). **SAFADI, Muhammad** [IL/IL]; c/o P.O. Box 50670, St. 5007 Apt. 5A, 16164 Nazareth (IL).

(74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2014/011750 A1

(54) Title: LAQUINIMOD FORMULATIONS WITHOUT ALKALIZING AGENT

(57) Abstract: The subject invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler, and an amount of a lubricant, wherein the stable pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent. The subject invention also provides processes for making the stable pharmaceutical composition and sealed packages comprising the stable pharmaceutical composition. The subject invention additionally provides method for treating a subject afflicted with a form of multiple sclerosis or for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis comprising administering to the subject a stable pharmaceutical composition as described herein. The subject invention further provides for use of a stable pharmaceutical composition as described herein for treating a subject afflicted with a form of multiple sclerosis or for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis.